Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > So are we on to the next big thing?

<< Previous

Bullboard Posts

Next >>

Comment by LouisWon Nov 15, 2021 6:41pm

165 Views

Post# 34129533

RE:RE:RE:RE:RE:So are we on to the next big thing?

To me, the results might be meaningful since those cancer cells from patient are considered primary cells. In preclinical study, THTX showed some result using cancer cell lines which are all immortalized cells. We actually don't know whether something is changed during the culture. And since Marsolais claimed the data will be published in 2022, I bet the result is great and consistent to their expectation.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale